The haemostatic system is tightly regulated to maintain homeostasis to avoid unwanted bleeding or thrombotic complications. Recent research has highlighted the importance of epigenetic changes, such as DNA methylation, histone modifications, and miRNA-based mechanisms, that alter gene expression. This can give rise to dysregulated haemostatic or vascular expressed molecules contributing to the development of thrombotic complications. Targeting these epigenetic changes could provide a new avenue for the treatment of pathological blood clots. However, the lack of tissue specificity warrants high-resolution genomic studies of the transcriptome and methylome that will reveal explicit epigenetic targets for the design of superior drugs with minimum off-target effects.

严格调节止血系统，以保持体内平衡，避免不必要的出血或血栓形成并发症。最近的研究强调了表观遗传变化的重要性，例如改变基因表达的DNA甲基化，组蛋白修饰和基于miRNA的机制。这会导致止血或血管表达分子失调，从而导致血栓并发症的发展。针对这些表观遗传学变化可以为病理性血凝块的治疗提供新的途径。然而，组织特异性的缺乏保证了转录组和甲基化组的高分辨率基因组研究，这些研究将揭示出明确的表观遗传学靶标，用于设计具有最小脱靶效应的优质药物。